Jagsonpal Pharma Q2 FY27 Results: Revenue ₹813.75 Cr, Net Profit ₹122.88 Cr
Jagsonpal Pharmaceuticals reported Q2 FY27 revenue of ₹813.75 crore and net profit of ₹122.88 crore. For H1 FY27, revenue was ₹1,636.07 crore and net profit was ₹254.76 crore. The company acquired an 85% stake in Aequitas Healthcare for ₹208 crore and finalized a Business Transfer Agreement for a Wellness Portfolio.
The announcement includes quarterly financial results, a significant acquisition, and a business transfer agreement, all of which are material events that can significantly impact the company's performance and stock value.
The company reported increased revenue and a strong profit, along with strategic acquisitions, indicating positive business performance and growth.
Jagsonpal Pharmaceuticals Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a revenue from operations of ₹813.75 crore for the quarter, compared to ₹744.65 crore in the same period last year. The net profit for the quarter stood at ₹122.88 crore, a significant increase from ₹132.83 crore in the previous year's corresponding quarter.
For the half-year ended September 30, 2026, the revenue from operations was ₹1,636.07 crore, up from ₹1,500.77 crore in the corresponding period of the previous year. The net profit for the half-year was ₹254.76 crore, compared to ₹256.71 crore in the prior year.
The Board of Directors met on October 28, 2026, to consider and approve these results. The meeting commenced at 4:30 p.m. and concluded at 4:56 p.m. The company also reported the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited for ₹208 crore, effective July 1, 2026, marking its entry into the hospital segment. Additionally, Jagsonpal entered into a Business Transfer Agreement on September 23, 2026, for the acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited, with closing formalities completed in October 2026.
The company declared a final dividend of ₹4 per equity share for the year ended March 31, 2026, amounting to ₹263.83 crore, which was approved at the Annual General Meeting held on September 18, 2026.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.